Please login to the form below

Not currently logged in
Email:
Password:

Arterial

This page shows the latest Arterial news and features for those working in and with pharma, biotech and healthcare.

Moderna inks R&D agreements with Vertex and Chiesi

Moderna inks R&D agreements with Vertex and Chiesi

Moderna has agreed to separate deals with Vertex and Chiesi for research and development spanning cystic fibrosis (CF) therapies and pulmonary arterial hypertension (PAH).

Latest news

More from news
Approximately 7 fully matching, plus 88 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    First-to-market generics included medicines for opioid overdose, pulmonary arterial hypertension, breast cancer, seizures, depression and various infections.

  • Is it time we stopped talking about adherence? Is it time we stopped talking about adherence?

    The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.

  • Mobile health and patient outcomes Mobile health and patient outcomes

    diabetes patients to remember their nutritional plan when in a supermarket or advising patients with pulmonary arterial hypertension that their average six-minute walking distance has decreased, prompting them to speak

  • The three forces behind the re-imagining of patient care The three forces behind the re-imagining of patient care

    Using apps to manage chronic conditions such as diabetes and asthma and rare disease such as pulmonary arterial hypertension can now be proven to improve clinical care.

  • Pharma deals in September 2015 Pharma deals in September 2015

    In an attempt to be hunter rather than hunted, and to diversify its portfolio from just PAH (pulmonary arterial hypertension), Actelion has acknowledged it is holding “preliminary discussions with ZS Pharma”.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Former Novartis vaccines CMO joins Arterial Former Novartis vaccines CMO joins Arterial

    Dr Markus Weissbach becomes clinical trials director. Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its ... David Evans, director of Arterial, said:

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics